$TMO

Time Out Media Arm Back in the Black as FY26 Revenue Climbs

Time Out Group's (TMO) Media arm returned to adjusted EBITDA profit with a 17% revenue increase to £21m. Group revenue was £72m, flat year-over-year. The company expanded its global audience by 31% to 280 million and opened new locations. CEO Chris Ohlund attributed the turnaround to strategic progress and operational improvements.

Original reporting
Published Sep 28, 2026, 9:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 1:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Time Out Media Arm Back in the Black as FY26 Revenue Climbs — source image
Decision brief

The 30-second read

$TMOBullishLow
01

Why it matters

The return to profitability signals operational turnaround, but the company's debt refinancing remains a key risk.

02

Market read

Primary relevance to TMO shareholders; secondary relevance to UK media sector and debt investors.

03

What to watch

Ongoing senior debt refinancing and related-party transactions could introduce volatility.

Relevance 6/10Novelty 6/10Timing: today

Background

Time Out Group operates a global media brand and physical market venues; the Media division had been loss-making prior to FY26.

Company-level read

Ticker impact

$TMOBullishMedium confidence
Context

Time Out Group (ticker TMO) reported its Media arm returned to adjusted EBITDA profit and revenue rose 17% to £21m for FY26.

Expected impact

likely upward pressure as investors price in the first EBITDA profit and revenue growth

Evidence & confidence

The new profitability and revenue increase are fresh disclosures that were not previously public, suggesting a favorable market reaction.

Market effects

Improves outlook for UK media and events sector, may lift peers with similar business models.

Modest boost to UK AIM market sentiment.

Limited; primarily relevant to investors tracking niche media companies.

Counterpoint

The profit may be temporary; debt refinancing risks could offset upside.

Key entities

  • Time Out Group

    AIM‑listed media and events company reporting FY26 results.

  • Oakley Capital

    Existing shareholder providing growth capital and conversion shares.

Related articles

$AXPMed

JPMorgan reveals stocks worth buying in October 2026

JPMorgan added five stocks to its Overweight list, highlighting American Express (AXP) as a Value pick, Thermo Fisher (TMO) and Liberty Energy (LBRT) as Growth picks. AXP is down 18-19% YTD but JPMorgan sees steady profits and share buybacks. TMO is up 25% in 3 months, with growth driven by partnerships and AI-powered lab machines. LBRT is up 52% in 12 months, benefiting from AI data center power demands.

$QNTMMed

Quantum BioPharma Taps Thermo Fisher for Lucid-MS Phase 2 Trial in Multiple Sclerosis

Quantum BioPharma (QNTM) has partnered with Thermo Fisher Scientific to begin Phase 2 trials for Lucid-MS, a treatment for progressive multiple sclerosis. The FDA has cleared the trial, which will assess efficacy, safety, and tolerability. Thermo Fisher will provide clinical research services. Success could offer a new treatment option for MS, a condition with limited therapies. Quantum owns 19.84% of Unbuzzd Wellness and receives royalties from it.

$QNTMMedAI 8/10

Quantum BioPharma Advances Multiple Sclerosis Trial with Thermo Fisher Partnership

Quantum BioPharma (QNTM) partnered with Thermo Fisher Scientific to start a Phase 2 trial for Lucid-MS, a treatment for progressive multiple sclerosis. The trial, cleared by the FDA, will assess efficacy, safety, and tolerability. Lucid-MS targets myelin degradation, differing from existing therapies. Quantum owns 19.84% of Unbuzzd Wellness, with royalty agreements in place.

$QNTMMed

Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis

Quantum BioPharma (QNTM) has signed a contract with Thermo Fisher Scientific to implement its Phase 2 clinical trial for Lucid-MS, a treatment for multiple sclerosis. The trial will evaluate the drug's efficacy, safety, and tolerability. Quantum BioPharma received FDA clearance to proceed with the study. The multiple sclerosis market is projected to exceed $38 billion by 2030, according to Grand View Research.